Skip To Main Content
Amleto Fiocchi on Muck Rack

Amleto Fiocchi

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Amleto

Contact Amleto, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Tumor-targeted interferon-α gene therapy for glioblastoma: a phase 1 trial

|
By Bernhard Gentner, Marica Eoli, Francesca Farina, Matteo Barcella, Alessia Capotondo, Antonio Francavilla, Matteo G. Carrabba, Valeria Ferla, Alessandro Bruno, Giorgia Alvisi, Eugenio Montini, Maria Grazia Bruzzone, Francesco Di Meco, Paolo Ferroli, Francesco Acerbi, Roberto Pallini, Quintino Giorgio D’Alessandris, Alessandro Olivi, Filippo Gagliardi, Silvia Snider, Pietro Mortini, Valeria Berno, Pietro Luigi Poliani, Carlo Russo, Fabio Ciceri, Luigi Naldini, Stefania Mazzoleni, Valentina Brambilla, Mariagrazia Garramone, Nadia Coltella, Leila Hadadi, Charlotte Capt, Valeria Cuccarini, Federico G. Legnani, Monica Patanè, Amleto Fiocchi, Gaetano Finocchiaro
| Nature Verified
Abstract Glioblastoma (GBM) is an immunologically cold brain tumor with poor outcome, characterized by a myeloid-driven immunosuppressive microenvironment. Here we report an interim analysis of a first-in-human phase 1/2a dose-escalation study evaluating Temferon—a genetically engineered autologous stem cell transplant designed to deliver interferon-α2 by means of myeloid progeny recruited to the GBM TME and locally activate antitumor immunity.
Open in Who Shared Issue with article?
See all 1 articles